Biohaven and Yale University say a U.S. District Court enters judgment in their favor in a trade secret dispute, awarding about $4 million. The companies report the decision formally confirms that RA Capital Management and Avilar Therapeutics willfully and maliciously misappropriated a trade secret they developed at Yale.
According to the filings and announcements cited by outlets, the ruling comes after court proceedings in the District of Delaware. Investing.com and PR Newswire both describe the outcome as a judgment that finalizes the award and ties it to findings of willful and malicious conduct. The reporting differs mainly in emphasis: PR Newswire highlights the judgment’s language and its effect on confirming the award, while Investing.com focuses on the headline result.
No further details about the underlying technology, damages calculation, or any appellate posture are provided in the excerpts supplied here, and the reports do not describe any immediate response from the defendants.
